David Hecht
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David Hecht has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Gary B. Fogel
Natural Selection, Inc., San Diego, CA USA 92121
12 shared publicationsJeffrey J.P. Tsai
6 shared publications- Jeffrey Louis Gustafson
Stony Brook University
5 shared publications Mars Cheung
Natural Selection, Inc. 9330 Scranton Rd., Suite 150, San Diego, CA 92121, USA
5 shared publications- Phillip Chen-Yu Sheu
Department of EECS, University of California, Irvine, USA
5 shared publications - Aparajita Chourasia4 shared publications
Latest Publications
- Open Access
- 30 November 2020
- Published by American Chemical Society (ACS)
Bioavailable dual-protein degraders of CK1α and transcriptional kinase CDK9 as potential therapeutics for hematological malignancies
- 30 November 2020
- Published by American Chemical Society (ACS)
Open AccessBioavailable dual-protein degraders of CK1α and transcriptional kinase CDK9 as potential therapeutics for hematological malignancies
- Open Access
- 30 November 2020
- Published by American Chemical Society (ACS)
Bioavailable dual-protein degraders of CK1α and transcriptional kinase CDK9 as potential therapeutics for hematological malignancies
- 30 November 2020
- Published by American Chemical Society (ACS)
Open AccessBioavailable dual-protein degraders of CK1α and transcriptional kinase CDK9 as potential therapeutics for hematological malignancies
- Open Access
- 30 November 2020
- Published by American Chemical Society (ACS)
Bioavailable dual-protein degraders of CK1α and transcriptional kinase CDK9 as potential therapeutics for hematological malignancies
- 30 November 2020
- Published by American Chemical Society (ACS)
Open AccessBioavailable dual-protein degraders of CK1α and transcriptional kinase CDK9 as potential therapeutics for hematological malignancies
- Open Access
- 30 November 2020
- Published by American Chemical Society (ACS)
Bioavailable dual-protein degraders of CK1α and transcriptional kinase CDK9 as potential therapeutics for hematological malignancies
- 30 November 2020
- Published by American Chemical Society (ACS)
Open AccessBioavailable dual-protein degraders of CK1α and transcriptional kinase CDK9 as potential therapeutics for hematological malignancies
- 1 May 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (9) , 127108
Discovery of cyclic guanidine-linked sulfonamides as inhibitors of LMTK3 kinase
- 1 May 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (9) , 127108
Discovery of cyclic guanidine-linked sulfonamides as inhibitors of LMTK3 kinase
- 31 January 2020
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 73 (3) , 212-221
Syntheses and Binding Testing of N1-Alkylamino-Substituted 2-Aminobenzimidazole Analogues Targeting the Hepatitis C Virus Internal Ribosome Entry Site*
A series of 2-aminobenzimidazole analogues have been synthesised and tested for binding to a previously established RNA target for viral translation inhibitors in the internal ribosome entry site (IRES) of the hepatitis C virus (HCV). Synthesis of new inhibitor compounds followed a highly convergent strategy which allowed for incorporation of diverse tertiary amino substituents in high overall yields (eight-steps, 4–22 %). Structure–activity relationship (SAR) studies focussed on the tertiary amine substituent involved in hydrogen bonding with the RNA backbone at the inhibitor binding site. The SAR study was further correlated with in silico docking experiments. Analogous compounds showed promising activities (half maximal effective concentration, EC50: 21–89 µM). Structures of the synthesised analogues and a correlation to their mode of binding, provided the opportunity to explore parameters required for selective targeting of the HCV IRES at the subdomain IIa which acts as an RNA conformational switch in HCV translation.
- 31 January 2020
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 73 (3) , 212-221
Syntheses and Binding Testing of N1-Alkylamino-Substituted 2-Aminobenzimidazole Analogues Targeting the Hepatitis C Virus Internal Ribosome Entry Site*
A series of 2-aminobenzimidazole analogues have been synthesised and tested for binding to a previously established RNA target for viral translation inhibitors in the internal ribosome entry site (IRES) of the hepatitis C virus (HCV). Synthesis of new inhibitor compounds followed a highly convergent strategy which allowed for incorporation of diverse tertiary amino substituents in high overall yields (eight-steps, 4–22 %). Structure–activity relationship (SAR) studies focussed on the tertiary amine substituent involved in hydrogen bonding with the RNA backbone at the inhibitor binding site. The SAR study was further correlated with in silico docking experiments. Analogous compounds showed promising activities (half maximal effective concentration, EC50: 21–89 µM). Structures of the synthesised analogues and a correlation to their mode of binding, provided the opportunity to explore parameters required for selective targeting of the HCV IRES at the subdomain IIa which acts as an RNA conformational switch in HCV translation.
- Open Access
Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells
Zika virus (ZIKV), an emerging flavivirus that causes neurodevelopmental impairment to fetuses and has been linked to Guillain-Barré syndrome continues to threaten global health due to the absence of targeted prophylaxis or treatment. Nucleoside analogues are good examples of efficient anti-viral inhibitors, and prodrug strategies using phosphate masking groups (ProTides) have been employed to improve the bioavailability of ribonucleoside analogues. Here, we synthesized and tested a small library of 13 ProTides against ZIKV in human neural stem cells. Strong activity was observed for 2′-C-methyluridine and 2′-C-ethynyluridine ProTides with an aryloxyl phosphoramidate masking group. Substitution of a 2-(methylthio) ethyl phosphoramidate for the aryloxyl phosphoramidate ProTide group of 2′-C-methyluridine completely abolished antiviral activity of the compound. The aryloxyl phosphoramidate ProTide of 2′-C-methyluridine outperformed the hepatitis C virus (HCV) drug sofosbuvir in suppression of viral titers and protection from cytopathic effect, while the former compound’s triphosphate active metabolite was better incorporated by purified ZIKV NS5 polymerase over time. These findings suggest both a nucleobase and ProTide group bias for the anti-ZIKV activity of nucleoside analogue ProTides in a disease-relevant cell model.
Open AccessActivity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells
Zika virus (ZIKV), an emerging flavivirus that causes neurodevelopmental impairment to fetuses and has been linked to Guillain-Barré syndrome continues to threaten global health due to the absence of targeted prophylaxis or treatment. Nucleoside analogues are good examples of efficient anti-viral inhibitors, and prodrug strategies using phosphate masking groups (ProTides) have been employed to improve the bioavailability of ribonucleoside analogues. Here, we synthesized and tested a small library of 13 ProTides against ZIKV in human neural stem cells. Strong activity was observed for 2′-C-methyluridine and 2′-C-ethynyluridine ProTides with an aryloxyl phosphoramidate masking group. Substitution of a 2-(methylthio) ethyl phosphoramidate for the aryloxyl phosphoramidate ProTide group of 2′-C-methyluridine completely abolished antiviral activity of the compound. The aryloxyl phosphoramidate ProTide of 2′-C-methyluridine outperformed the hepatitis C virus (HCV) drug sofosbuvir in suppression of viral titers and protection from cytopathic effect, while the former compound’s triphosphate active metabolite was better incorporated by purified ZIKV NS5 polymerase over time. These findings suggest both a nucleobase and ProTide group bias for the anti-ZIKV activity of nucleoside analogue ProTides in a disease-relevant cell model.
- 1 January 2018
- Published by Elsevier in Tuberculosis
- Vol. 108, 155-162
Modeling the structural origins of drug resistance to isoniazid via key mutations in Mycobacterium tuberculosis catalase-peroxidase, KatG
- 1 January 2018
- Published by Elsevier in Tuberculosis
- Vol. 108, 155-162
Modeling the structural origins of drug resistance to isoniazid via key mutations in Mycobacterium tuberculosis catalase-peroxidase, KatG
- 1 January 2017
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 71, 135-153
Structure-based analysis of Bacilli and plasmid dihydrofolate reductase evolution
- 1 January 2017
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 71, 135-153
Structure-based analysis of Bacilli and plasmid dihydrofolate reductase evolution
- Open Access
- 30 June 2016
- Published by Wiley in Biochemistry and Molecular Biology Education
- Vol. 45 (1) , 7-12
CUREs in biochemistry—where we are and where we should go
Integration of research experience into classroom is an important and vital experience for all undergraduates. These course‐based undergraduate research experiences (CUREs) have grown from independent instructor lead projects to large consortium driven experiences. The impact and importance of CUREs on students at all levels in biochemistry was the focus of a National Science Foundation funded think tank. The state of biochemistry CUREs and suggestions for moving biochemistry forward as well as a practical guide (supplementary material) are reported here. © 2016 by The International Union of Biochemistry and Molecular Biology, 45(1):7–12, 2017.
- 30 June 2016
- Published by Wiley in Biochemistry and Molecular Biology Education
- Vol. 45 (1) , 7-12
Open AccessCUREs in biochemistry—where we are and where we should go
Integration of research experience into classroom is an important and vital experience for all undergraduates. These course‐based undergraduate research experiences (CUREs) have grown from independent instructor lead projects to large consortium driven experiences. The impact and importance of CUREs on students at all levels in biochemistry was the focus of a National Science Foundation funded think tank. The state of biochemistry CUREs and suggestions for moving biochemistry forward as well as a practical guide (supplementary material) are reported here. © 2016 by The International Union of Biochemistry and Molecular Biology, 45(1):7–12, 2017.